Pfizer Inc. announced
that it has completed the acquisition of GlaxoSmithKline’s quadrivalent
meningococcal ACWY vaccines Nimenrix and Mencevax.
Nimenrix (meningococcal serogroups A,
C, W-135 and Y conjugate vaccine) is a single-dose meningococcal ACWY-TT
(tetanus toxoid) conjugated vaccine designed to protect against
Neisseria meningitidis, an uncommon but highly contagious disease that
can lead to disability and death. It is indicated for all age groups
above one year of age. Launched three years ago, Nimenrix is currently
registered and approved for sale in 63 countries across the European
Economic Area (EEA 30), Canada, Australia and Emerging Markets, with
registrations under review in another 17 countries across Africa, Asia,
Eastern Europe and the Middle East.
Mencevax (meningococcal polysaccharide
serogroups A, C, Y and W-135 vaccine) is a single-dose meningococcal
ACWY unconjugated polysaccharide vaccine used to control outbreaks of
meningococcal infection and for travelers in countries where the disease
is endemic or highly epidemic. Mencevax is indicated for use across all
age groups from 2 years of age, and is currently registered and
approved in 78 countries across Africa, Asia, Australia, Europe, Latin
America, Middle East and New Zealand.
